Global Psychoactive Drug Market Forecast and Analysis (2019-2026), by Type, by Application, by Region.

Global Psychoactive Drug Market Forecast and Analysis (2019-2026), by Type, by Application, by Region.

Market Scenario

Global Psychoactive Drug Market was valued at US$ XX million in 2018 and is expected to reach US$ XX million by 2026 at a CAGR of xx% over forecast period 2019-2026.Global Psychoactive Drug Market Segmentation by RegionA psychoactive drugs changes brain function and results in alterations in perception, mood, behaviour, consciousness and cognition. These substances are be used medically, recreationally, to purposefully improve performance or alter one’s consciousness entheogens for ritual, spiritual, shamanic purpose or for research. The global psychoactive drug market is mainly driven by, Rise in R&D expenditure, increased prevalence of diseases across the globe, increased geriatric population, rise in awareness regarding various diseases in developing countries, and rich pipeline of innovative treatment options are some factors that are expected to boost the global psychoactive drugs market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the global psychoactive drugs market over the forecast period. Psychoactive drugs misuse, dependence and addiction have resulted in legal measures and moral debate. Governmental controls on manufacture, supply and prescription attempt to reduce problematic medical drug use. Ethical Concerns have also been raised about over-use of these drugs clinically, and about their marketing by manufacturers. Stringent government regulations, high cost of advanced treatments and severe side-effects associated with certain injectable treatments are expected to hamper the psychoactive drugs market. Global Psychoactive Drug Market is segmented by type, by application and by region. By type market is segmented into stimulants, depressants, narcotics, hallucinogens, cannabis and others. Stimulate segment is expected to exhibit highest global market share at a CAGR of XX% over forecast period. Stimulants range from nicotine and caffeine to cocaine and crystal meth. Stimulants block the reuptake or reabsorption of neurotransmitters like serotonin and dopamine, which can lead to increased energy, panic and anxiety. By geography, the global psychoactive drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global psychoactive drugs market owing to the low cost of manufacturing, acceptable regulatory scenario and presence of major players in the region. Moreover, the market in Asia Pacific is projected to grow at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development and increasing disposable income in countries such as China and India, and Japan. Key players operating in global psychoactive drug market are Abbott Laboratories (U.S.), Sanofi S.A. (France), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India). These Drug companies discovered a way to synthesize medications rather than having to rely on extracts from natural products. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global psychoactive drug market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the global psychoactive drug market.

Global Psychoactive Drug Market Segmentation by Types

• Stimulants • Depressants • Narcotics • Hallucinogens • Cannabis • Others (Inhalants, sports drugs, psychiatric medications, compulsive behaviours)

Global Psychoactive Drug Market Segmentation by Application

• Anaesthesia • Pain management • Mental disorders • Recreation • Ritual and spiritual • Others

Global Psychoactive Drug Market Segmentation by Region

• North America • Europe • APAC • MEA& Africa • Latin America

Global Psychoactive Drug Market Major players

• Abbott Laboratories (U.S.) • Sanofi S.A. (France) • Cipla Limited (India) • Biocon Limited (India) • Intas Pharmaceuticals Ltd. (India) • Sun Pharmaceutical Industries Ltd. (India) • Cadila Pharmaceuticals (India) • Lupin Limited (India) • Emcure Pharmaceuticals Ltd. (India) • Novartis International AG (Switzerland) • Dr. Reddy’s Laboratories Limited (India) • Alkem Laboratories Limited (India) Global Dental Chair Market

Table of Contents

Global Psychoactive Drug Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Psychoactive Drugs Market, by Market Value (US$ Mn) and Volume(Ton) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Psychoactive Drugs Market Analysis and Forecast 6.1. Global Psychoactive Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Psychoactive Drugs Market Analysis and Forecast, by Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Psychoactive Drugs Market Value Share Analysis, by Application 7.4. Global Psychoactive Drugs Market Size (US$ Mn) Forecast, by Application 7.5. Global Psychoactive Drugs Market Analysis, by Application 7.6. Global Psychoactive Drugs Market Attractiveness Analysis, by Application 8. Global Psychoactive Drugs Market Analysis and Forecast, by Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Psychoactive Drugs Market Value Share Analysis, by Type 8.4. Global Psychoactive Drugs Market Size (US$ Mn) Forecast, by Type 8.5. Global Psychoactive Drugs Market Analysis, by Type 8.6. Global Psychoactive Drugs Market Attractiveness Analysis, by Type 9. Global Psychoactive Drugs Market Analysis, by Region 9.1. Global Psychoactive Drugs Market Value Share Analysis, by Region 9.2. Global Psychoactive Drugs Market Size (US$ Mn) Forecast, by Region 9.3. Global Psychoactive Drugs Market Attractiveness Analysis, by Region 10. North America Psychoactive Drugs Market Analysis 10.1. Key Findings 10.2. North America Psychoactive Drugs Market Overview 10.3. North America Psychoactive Drugs Market Value Share Analysis, by Application 10.4. North America Psychoactive Drugs Market Forecast, by Application 10.4.1. Anaesthesia 10.4.2. Pain management 10.4.3. Mental disorders 10.4.4. Recreation 10.4.5. Ritual and spiritual 10.4.6. Others 10.5. North America Psychoactive Drugs Market Value Share Analysis, by Type 10.6. North America Psychoactive Drugs Market Forecast, by Type 10.6.1. Stimulants 10.6.2. Depressants 10.6.3. Narcotics 10.6.4. Hallucinogens 10.6.5. Cannabis 10.6.6. Others 10.7. North America Psychoactive Drugs Market Value Share Analysis, by Country 10.8. North America Psychoactive Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Psychoactive Drugs Market Analysis, by Country 10.10. U.S. Psychoactive Drugs Market Forecast, by Application 10.10.1. Anaesthesia 10.10.2. Pain management 10.10.3. Mental disorders 10.10.4. Recreation 10.10.5. Ritual and spiritual 10.10.6. Others 10.11. U.S. Psychoactive Drugs Market Forecast, by Type 10.11.1. Stimulants 10.11.2. Depressants 10.11.3. Narcotics 10.11.4. Hallucinogens 10.11.5. Cannabis 10.11.6. Others 10.12. Canada Psychoactive Drugs Market Forecast, by Application 10.12.1. Anaesthesia 10.12.2. Pain management 10.12.3. Mental disorders 10.12.4. Recreation 10.12.5. Ritual and spiritual 10.12.6. Others 10.13. Canada Psychoactive Drugs Market Forecast, by Type 10.13.1. Stimulants 10.13.2. Depressants 10.13.3. Narcotics 10.13.4. Hallucinogens 10.13.5. Cannabis 10.13.6. Others 10.14. North America Psychoactive Drugs Market Attractiveness Analysis 10.14.1. By Application 10.14.2. By Type 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Psychoactive Drugs Market Analysis 11.1. Key Findings 11.2. Europe Psychoactive Drugs Market Overview 11.3. Europe Psychoactive Drugs Market Value Share Analysis, by Application 11.4. Europe Psychoactive Drugs Market Forecast, by Application 11.4.1. Anesthesia 11.4.2. Pain management 11.4.3. Mental disorders 11.4.4. Recreation 11.4.5. Ritual and spiritual 11.4.6. Others 11.5. Europe Psychoactive Drugs Market Value Share Analysis, by Type 11.6. Europe Psychoactive Drugs Market Forecast, by Type 11.6.1. Stimulants 11.6.2. Depressants 11.6.3. Narcotics 11.6.4. Hallucinogens 11.6.5. Cannabis 11.6.6. Others 11.7. Europe Psychoactive Drugs Market Value Share Analysis, by Country 11.8. Europe Psychoactive Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Psychoactive Drugs Market Analysis, by Country 11.10. Germany Psychoactive Drugs Market Forecast, by Application 11.10.1. Anesthesia 11.10.2. Pain management 11.10.3. Mental disorders 11.10.4. Recreation 11.10.5. Ritual and spiritual 11.10.6. Others 11.11. Germany Psychoactive Drugs Market Forecast, by Type 11.11.1. Stimulants 11.11.2. Depressants 11.11.3. Narcotics 11.11.4. Hallucinogens 11.11.5. Cannabis 11.11.6. Others 11.12. U.K. Psychoactive Drugs Market Forecast, by Application 11.12.1. Anaesthesia 11.12.2. Pain management 11.12.3. Mental disorders 11.12.4. Recreation 11.12.5. Ritual and spiritual 11.12.6. Others 11.13. U.K. Psychoactive Drugs Market Forecast, by Type 11.13.1. Stimulants 11.13.2. Depressants 11.13.3. Narcotics 11.13.4. Hallucinogens 11.13.5. Cannabis 11.13.6. Others 11.14. France Psychoactive Drugs Market Forecast, by Application 11.14.1. Anaesthesia 11.14.2. Pain management 11.14.3. Mental disorders 11.14.4. Recreation 11.14.5. Ritual and spiritual 11.14.6. Others 11.15. France Psychoactive Drugs Market Forecast, by Type 11.15.1. Stimulants 11.15.2. Depressants 11.15.3. Narcotics 11.15.4. Hallucinogens 11.15.5. Cannabis 11.15.6. Others 11.16. Italy Psychoactive Drugs Market Forecast, by Application 11.16.1. Anaesthesia 11.16.2. Pain management 11.16.3. Mental disorders 11.16.4. Recreation 11.16.5. Ritual and spiritual 11.16.6. Others 11.17. Italy Psychoactive Drugs Market Forecast, by Type 11.17.1. Stimulants 11.17.2. Depressants 11.17.3. Narcotics 11.17.4. Hallucinogens 11.17.5. Cannabis 11.17.6. Others 11.18. Spain Psychoactive Drugs Market Forecast, by Application 11.18.1. Anesthesia 11.18.2. Pain management 11.18.3. Mental disorders 11.18.4. Recreation 11.18.5. Ritual and spiritual 11.18.6. Others 11.19. Spain Psychoactive Drugs Market Forecast, by Type 11.19.1. Stimulants 11.19.2. Depressants 11.19.3. Narcotics 11.19.4. Hallucinogens 11.19.5. Cannabis 11.19.6. Others 11.20. Rest of Europe Psychoactive Drugs Market Forecast, by Application 11.20.1. Anesthesia 11.20.2. Pain management 11.20.3. Mental disorders 11.20.4. Recreation 11.20.5. Ritual and spiritual 11.20.6. Others 11.21. Rest of Europe Psychoactive Drugs Market Forecast, by Type 11.21.1. Stimulants 11.21.2. Depressants 11.21.3. Narcotics 11.21.4. Hallucinogens 11.21.5. Cannabis 11.21.6. Others 11.22. Europe Psychoactive Drugs Market Attractiveness Analysis 11.22.1. By Application 11.22.2. By Type 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Development 12. Asia Pacific Psychoactive Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Psychoactive Drugs Market Overview 12.3. Asia Pacific Psychoactive Drugs Market Value Share Analysis, by Application 12.4. Asia Pacific Psychoactive Drugs Market Forecast, by Application 12.4.1. Anesthesia 12.4.2. Pain management 12.4.3. Mental disorders 12.4.4. Recreation 12.4.5. Ritual and spiritual 12.4.6. Others 12.5. Asia Pacific Psychoactive Drugs Market Value Share Analysis, by Type 12.6. Asia Pacific Psychoactive Drugs Market Forecast, by Type 12.6.1. Stimulants 12.6.2. Depressants 12.6.3. Narcotics 12.6.4. Hallucinogens 12.6.5. Cannabis 12.6.6. Others 12.7. Asia Pacific Psychoactive Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Psychoactive Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Psychoactive Drugs Market Analysis, by Country 12.10. China Psychoactive Drugs Market Forecast, by Application 12.10.1. Anesthesia 12.10.2. Pain management 12.10.3. Mental disorders 12.10.4. Recreation 12.10.5. Ritual and spiritual 12.10.6. Others 12.11. China Psychoactive Drugs Market Forecast, by Type 12.11.1. Stimulants 12.11.2. Depressants 12.11.3. Narcotics 12.11.4. Hallucinogens 12.11.5. Cannabis 12.11.6. Others 12.12. India Psychoactive Drugs Market Forecast, by Application 12.12.1. Anesthesia 12.12.2. Pain management 12.12.3. Mental disorders 12.12.4. Recreation 12.12.5. Ritual and spiritual 12.12.6. Others 12.13. India Psychoactive Drugs Market Forecast, by Type 12.13.1. Stimulants 12.13.2. Depressants 12.13.3. Narcotics 12.13.4. Hallucinogens 12.13.5. Cannabis 12.13.6. Others 12.14. Japan Psychoactive Drugs Market Forecast, by Application 12.14.1. Anesthesia 12.14.2. Pain management 12.14.3. Mental disorders 12.14.4. Recreation 12.14.5. Ritual and spiritual 12.14.6. Others 12.15. Japan Psychoactive Drugs Market Forecast, by Type 12.15.1. Stimulants 12.15.2. Depressants 12.15.3. Narcotics 12.15.4. Hallucinogens 12.15.5. Cannabis 12.15.6. Others 12.16. ASEAN Psychoactive Drugs Market Forecast, by Application 12.16.1. Anesthesia 12.16.2. Pain management 12.16.3. Mental disorders 12.16.4. Recreation 12.16.5. Ritual and spiritual 12.16.6. Others 12.17. ASEAN Psychoactive Drugs Market Forecast, by Type 12.17.1. Stimulants 12.17.2. Depressants 12.17.3. Narcotics 12.17.4. Hallucinogens 12.17.5. Cannabis 12.17.6. Others 12.18. Rest of Asia Pacific Psychoactive Drugs Market Forecast, by Application 12.18.1. Anesthesia 12.18.2. Pain management 12.18.3. Mental disorders 12.18.4. Recreation 12.18.5. Ritual and spiritual 12.18.6. Others 12.19. Rest of Asia Pacific Psychoactive Drugs Market Forecast, by Type 12.19.1. Stimulants 12.19.2. Depressants 12.19.3. Narcotics 12.19.4. Hallucinogens 12.19.5. Cannabis 12.19.6. Others 12.20. Asia Pacific Psychoactive Drugs Market Attractiveness Analysis 12.20.1. By Application 12.20.2. By Type 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Development 13. Middle East & Africa Psychoactive Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Psychoactive Drugs Market Overview 13.3. Middle East & Africa Psychoactive Drugs Market Value Share Analysis, by Application 13.4. Middle East & Africa Psychoactive Drugs Market Forecast, by Application 13.4.1. Anesthesia 13.4.2. Pain management 13.4.3. Mental disorders 13.4.4. Recreation 13.4.5. Ritual and spiritual 13.4.6. Others 13.5. Middle East & Africa Psychoactive Drugs Market Value Share Analysis, by Type 13.6. Middle East & Africa Psychoactive Drugs Market Forecast, by Type 13.6.1. Stimulants 13.6.2. Depressants 13.6.3. Narcotics 13.6.4. Hallucinogens 13.6.5. Cannabis 13.6.6. Others 13.7. Middle East & Africa Psychoactive Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Psychoactive Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Psychoactive DrugsMarket Analysis, by Country 13.10. GCC Psychoactive DrugsMarket Forecast, by Application 13.10.1. Anesthesia 13.10.2. Pain management 13.10.3. Mental disorders 13.10.4. Recreation 13.10.5. Ritual and spiritual 13.10.6. Others 13.11. GCC Psychoactive Drugs Market Forecast, by Type 13.11.1. Stimulants 13.11.2. Depressants 13.11.3. Narcotics 13.11.4. Hallucinogens 13.11.5. Cannabis 13.11.6. Others 13.12. South Africa Psychoactive Drugs Market Forecast, by Application 13.12.1. Anesthesia 13.12.2. Pain management 13.12.3. Mental disorders 13.12.4. Recreation 13.12.5. Ritual and spiritual 13.12.6. Others 13.13. South Africa Psychoactive Drugs Market Forecast, by Type 13.13.1. Stimulants 13.13.2. Depressants 13.13.3. Narcotics 13.13.4. Hallucinogens 13.13.5. Cannabis 13.13.6. Others 13.14. Rest of Middle East & Africa Psychoactive Drugs Market Forecast, by Application 13.14.1. Anesthesia 13.14.2. Pain management 13.14.3. Mental disorders 13.14.4. Recreation 13.14.5. Ritual and spiritual 13.14.6. Others 13.15. Rest of Middle East & Africa Psychoactive Drugs Market Forecast, by Type 13.15.1. Stimulants 13.15.2. Depressants 13.15.3. Narcotics 13.15.4. Hallucinogens 13.15.5. Cannabis 13.15.6. Others 13.16. Middle East & Africa Psychoactive Drugs Market Attractiveness Analysis 13.16.1. By Application 13.16.2. By Type 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Development 14. South America Psychoactive Drugs Market Analysis 14.1. Key Findings 14.2. South America Psychoactive Drugs Market Overview 14.3. South America Psychoactive Drugs Market Value Share Analysis, by Application 14.4. South America Psychoactive Drugs Market Forecast, by Application 14.4.1. Anesthesia 14.4.2. Pain management 14.4.3. Mental disorders 14.4.4. Recreation 14.4.5. Ritual and spiritual 14.4.6. Others 14.5. South America Psychoactive Drugs Market Value Share Analysis, by Type 14.6. South America Psychoactive Drugs Market Forecast, by Type 14.6.1. Stimulants 14.6.2. Depressants 14.6.3. Narcotics 14.6.4. Hallucinogens 14.6.5. Cannabis 14.6.6. Others 14.7. South America Psychoactive Drugs Market Value Share Analysis, by Country 14.8. South America Psychoactive Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Psychoactive Drugs Market Analysis, by Country 14.10. Brazil Psychoactive Drugs Market Forecast, by Application 14.10.1. Anesthesia 14.10.2. Pain management 14.10.3. Mental disorders 14.10.4. Recreation 14.10.5. Ritual and spiritual 14.10.6. Others 14.11. Brazil Psychoactive Drugs Market Forecast, by Type 14.11.1. Stimulants 14.11.2. Depressants 14.11.3. Narcotics 14.11.4. Hallucinogens 14.11.5. Cannabis 14.11.6. Others 14.12. Mexico Psychoactive Drugs Market Forecast, by Application 14.12.1. Anaesthesia 14.12.2. Pain management 14.12.3. Mental disorders 14.12.4. Recreation 14.12.5. Ritual and spiritual 14.12.6. Others 14.13. Mexico Psychoactive Drugs Market Forecast, by Type 14.13.1. Stimulants 14.13.2. Depressants 14.13.3. Narcotics 14.13.4. Hallucinogens 14.13.5. Cannabis 14.13.6. Others 14.14. Rest of South America Psychoactive Drugs Market Forecast, by Application 14.14.1. Anesthesia 14.14.2. Pain management 14.14.3. Mental disorders 14.14.4. Recreation 14.14.5. Ritual and spiritual 14.14.6. Others 14.15. Rest of South America Psychoactive Drugs Market Forecast, by Type 14.15.1. Stimulants 14.15.2. Depressants 14.15.3. Narcotics 14.15.4. Hallucinogens 14.15.5. Cannabis 14.15.6. Others 14.16. South America Psychoactive Drugs Market Attractiveness Analysis 14.16.1. By Application 14.16.2. By Type 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Abbott Laboratories (U.S.) 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Sanofi S.A. (France) 15.3.3. Cipla Limited (India) 15.3.4. Biocon Limited (India) 15.3.5. Intas Pharmaceuticals Ltd. (India) 15.3.6. Sun Pharmaceutical Industries Ltd. (India) 15.3.7. Cadila Pharmaceuticals (India) 15.3.8. Lupin Limited (India) 15.3.9. Emcure Pharmaceuticals Ltd. (India) 15.3.10. Novartis International AG (Switzerland) 15.3.11. Dr. Reddy’s Laboratories Limited (India) 15.3.12. Alkem Laboratories Limited (India) 16. Primary Key Insights

About This Report

Report ID36268
Published DateNov 2019
Contact Us
Call Now